369 related articles for article (PubMed ID: 31699977)
1. AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.
Fok JHL; Ramos-Montoya A; Vazquez-Chantada M; Wijnhoven PWG; Follia V; James N; Farrington PM; Karmokar A; Willis SE; Cairns J; Nikkilä J; Beattie D; Lamont GM; Finlay MRV; Wilson J; Smith A; O'Connor LO; Ling S; Fawell SE; O'Connor MJ; Hollingsworth SJ; Dean E; Goldberg FW; Davies BR; Cadogan EB
Nat Commun; 2019 Nov; 10(1):5065. PubMed ID: 31699977
[TBL] [Abstract][Full Text] [Related]
2. The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases.
Anastasia A; Dellavedova G; Ramos-Montoya A; James N; Chiorino G; Russo M; Baakza H; Wilson J; Ghilardi C; Cadogan EB; Giavazzi R; Bani MR
Mol Cancer Ther; 2022 Apr; 21(4):555-567. PubMed ID: 35149547
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.
Nakamura K; Karmokar A; Farrington PM; James NH; Ramos-Montoya A; Bickerton SJ; Hughes GD; Illidge TM; Cadogan EB; Davies BR; Dovedi SJ; Valge-Archer V
Clin Cancer Res; 2021 Aug; 27(15):4353-4366. PubMed ID: 34011558
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
5. The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-
Goldberg FW; Finlay MRV; Ting AKT; Beattie D; Lamont GM; Fallan C; Wrigley GL; Schimpl M; Howard MR; Williamson B; Vazquez-Chantada M; Barratt DG; Davies BR; Cadogan EB; Ramos-Montoya A; Dean E
J Med Chem; 2020 Apr; 63(7):3461-3471. PubMed ID: 31851518
[TBL] [Abstract][Full Text] [Related]
6. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
7. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
9. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
10. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
[TBL] [Abstract][Full Text] [Related]
11. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
12. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks.
Jiang Y; Yam JC; Chu WK
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028
[TBL] [Abstract][Full Text] [Related]
13. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H
Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624
[TBL] [Abstract][Full Text] [Related]
14. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
15. The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Park HJ; Bae JS; Kim KM; Moon YJ; Park SH; Ha SH; Hussein UK; Zhang Z; Park HS; Park BH; Moon WS; Kim JR; Jang KY
J Exp Clin Cancer Res; 2018 May; 37(1):107. PubMed ID: 29784019
[TBL] [Abstract][Full Text] [Related]
16. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
18. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
[TBL] [Abstract][Full Text] [Related]
19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
[TBL] [Abstract][Full Text] [Related]
20. Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells.
Azad A; Bukczynska P; Jackson S; Haupt Y; Cullinane C; McArthur GA; Solomon B
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):385-94. PubMed ID: 24411611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
